Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer
18.11.2020 15:00:00 EET | Business Wire | Press release
Agendia, Inc., a world leader in precision oncology for breast cancer, and Paige, a global leader in AI-based digital diagnostics, today announced a first of its kind strategic partnership that will redefine precision oncology. The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005250/en/
“Paige’s digital pathology platform is truly transformational for oncology and will catapult diagnostics forward as a whole. This partnership defines the democratization of treatment planning tools by accelerating access to these tests and the essential insights they provide for more patients globally,” said Mark Straley, Chief Executive Officer of Agendia. “Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue ‘send out’ is not allowed. Whether a patient is in Manhattan or Mumbai, the ability to get real-time and accurate results from Agendia’s MammaPrint and BluePrint tests will improve how we are treating breast cancer today.”
The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead. This can be especially important for patients with operable breast cancer. Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting where a multitude of therapeutic options can add to the complexity of treatment planning.
“As the first company to receive FDA clearance, FDA breakthrough designation and two CE marks for digital and computational pathology products, Paige is delivering next-generation digital diagnostics that redefine how we approach cancer care,” said Leo Grady, Ph.D., Chief Executive Officer of Paige. “By combining our unique capabilities with Agendia’s leadership in breast cancer, we believe this innovative partnership can achieve our shared goal of transforming clear and actionable information into precision treatment for better patient outcomes. It will be the first of many AI-based diagnostic tests to come.”
For more information, please visit Agendia.com and Paige.ai.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSKCC). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
For additional information, please visit: https://www.Paige.ai, https://www.paigeplatform.com , Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005250/en/
Contact information
For Media:
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com
For Agendia Investors:
Mike Cavanaugh
Westwicke/ICR Healthcare IR
Tel: 617.877.9641
Mike.Cavanaugh@westwicke.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nanochon Performs First Case in the Chondrograft™ First-in-Human Clinical Study8.9.2026 16:47:00 EEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects of the knee, today announced the successful treatment of the first patient in its First-in-Human (FIH) clinical study. The study is designed to evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee. Dr. Juan Osorio and Dr. Emilio Tufiño, who both specialize in regenerative sports medicine, performed the first procedure at The Panama Clinic, Panamá. “I am pleased to be the Principal Investigator for this important study, and we are excited to be the first to initiate clinical study enrollment. The team here in Panamá looks forward to contributing the data that will support a larger clinical study and subsequent market entry,” stated Dr. Osorio. “The speed at which Dr. Osorio and the clinical team were able to identify, enroll, and treat the first patient underscores the significant unmet clini
Andersen Global Establishes New Member Firm in France8.9.2026 16:30:00 EEST | Press release
Andersen Global adds depth to its presence in France with the addition of Andersen Société d'Avocats (Andersen in France), a Paris-based member firm offering integrated legal capabilities to clients in France and internationally. Andersen in France provides strategic legal solutions on matters involving corporate tax, international tax, transfer pricing, VAT, and tax litigation, supporting clients around the world. Under the leadership of managing partners Benoît Dambre and François Morazin, the multidisciplinary team also handles specialized matters involving urban planning, real estate, intellectual property and privacy, sustainability and ESG, EU law and sanctions, and other complex legal issues. “We see legal advice as more than addressing immediate challenges; it should help clients make informed decisions and pursue opportunities with confidence,” said Benoît. “Becoming a member firm of Andersen Global allows us to combine that client-focused approach with broader international c
AI Can Design the Slides, But It Can’t Fix Stage Fright: 3 in 4 Workers Get Anxious Presenting, Canva Study Finds8.9.2026 16:00:00 EEST | Press release
New research from Canva, the world’s leading visual communication platform, reveals an emerging paradox at the heart of one of work’s age-old skills: even as AI makes presentations easier to create than ever, nearly three in four professionals (74%) still feel anxious about presenting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908549712/en/ Canva's Global 'The Presentation Paradox' Study Few things are as entrenched as presentations, and decade after decade, they’ve defined how we communicate to clients, teammates, leadership, and beyond. Now, AI is changing them by making them faster and easier to create than ever. Nine in 10 (91%) workers use AI monthly to build slides, mainly for design (57%), brainstorming (56%) and drafting content (49%). 48% say it saves them more than an hour per presentation. As AI use grows, more than 100 million people create presentations on Canva every month, and it is one of the top use
PAX Debuts The Oxblood Edit, a Limited Edition Collection Inspired by Fall’s Richest Color8.9.2026 16:00:00 EEST | Press release
Today PAX, a pioneering global cannabis brand, introduces The Oxblood Edit, an ultra-limited release bringing one of fall’s defining colors to three of the brand’s signature devices: PAX FOUR, PAX MINI and ERA GO. Deep, distinctive and designed to be coveted, Oxblood transforms the PAX lineup through a rich burgundy finish inspired by the worlds of fashion, interiors and industrial design. The limited collection is available beginning today at pax.com and select retailers, while supplies last. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908330141/en/ The Oxblood Edit: bringing timeless style, seasonal color, and elevated design to three of the brand's signature devices. Long associated with craftsmanship and enduring style, oxblood has reemerged across fashion, footwear, accessories and interiors as consumers gravitate toward richer palettes, timeless materials and elevated essentials. For PAX, the color is less about
STARTEEPO Issues Letter and Presentation to the Board of Xerox Calling for Action to Unlock Shareholder Value8.9.2026 16:00:00 EEST | Press release
STARTEEPO SICAV a.s. (“STARTEEPO”) today issued an investor presentation and the following letter to the Board of Directors (the “Board”) of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX). STARTEEPO, which has increased its investment in Xerox to a beneficial ownership of 7.34%, in stocks and options, is urging the Board to take bold actions to unlock significant shareholder value, including by increasing transparency about Xerox Financial Services’ performance, evaluating strategic alternatives for the business unit, deleveraging the Company, and exercising continued capital discipline. Shareholders can view the investor presentation here. For more information visit: www.starteepo.com/xerox. The full text of the letter follows: September 7, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Since we first wrote to you in May, we have increased our already significant investment in Xerox Holdings Corp. to a b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom